|
Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
|
28 September 2017 |
|
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
|
22 September 2017 |
|
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
|
15 September 2017 |
|
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019)
|
31 August 2017 |
|
Novartis appoints Bertrand Bodson as Chief Digital Officer
|
24 August 2017 |
|
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
|
21 August 2017 |
|
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
|
26 July 2017 |
|
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
|
14 July 2017 |
|
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
|
12 July 2017 |
|
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
|
22 June 2017 |